Cyclodextrin-Tirapazamine Complexes for Hypoxic Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are ineffective due to the hypoxic tumor microenvironment, which promotes therapeutic resistance and metastasis, and existing hypoxia-targeting agents like tirapazamine face challenges with toxicity and limited efficacy.
Innovation Solution
Development of cyclodextrin inclusion complexes with tirapazamine (TPZ) to enhance its delivery and cytotoxicity under hypoxic conditions, addressing the limitations of tirapazamine's toxicity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tirapazamine is administered to target hypoxic tumor cells, then therapeutic efficacy against HCC is improved, but toxicity increases limiting clinical application
Solution Approach 1:
The patent uses cyclodextrin molecules as intermediary carriers to deliver tirapazamine to hypoxic tumor cells. The cyclodextrin-tirapazamine inclusion complex serves as a mediator that enables targeted delivery, improving therapeutic efficacy while reducing systemic toxicity through controlled release and selective accumulation in hypoxic regions.
Solution Approach 2:
The patent modifies the physical and chemical parameters of tirapazamine by forming inclusion complexes with cyclodextrin. This changes the solubility, stability, and biodistribution characteristics of the drug, allowing for improved therapeutic window and reduced toxicity while maintaining hypoxia-selective activation.
2Ease of operation
If conventional treatments are used for HCC, then treatment simplicity is maintained, but efficacy is reduced due to hypoxia-induced resistance
Solution Approach 1:
The patent exploits the parameter change in oxygen concentration (hypoxic conditions) to activate tirapazamine selectively in tumor cells. This biochemical parameter-based activation mechanism maintains treatment simplicity while overcoming hypoxia-induced resistance through selective cytotoxicity in low-oxygen environments.
Solution Approach 2:
The patent converts the harmful hypoxic microenvironment that promotes tumor resistance into a beneficial selective trigger for drug activation. The hypoxic conditions that normally protect tumor cells are transformed into the specific condition that activates tirapazamine cytotoxicity, turning the tumor's defensive mechanism into its vulnerability.
3Reliability
If tirapazamine delivery is enhanced to improve efficacy, then selectivity for hypoxic cells increases, but formulation complexity increases
Solution Approach 1:
The patent employs cyclodextrin as a biocompatible intermediary molecule that naturally provides targeted delivery capabilities. The cyclodextrin-tirapazamine inclusion complex achieves enhanced selectivity for hypoxic cells through the inherent properties of cyclodextrin carriers, avoiding the need for complex engineered delivery systems while maintaining high selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclodextrin inclusion complexes improve tirapazamine's selectivity and efficacy in targeting hypoxic tumor cells, potentially overcoming therapeutic resistance and enhancing treatment outcomes for HCC.
Implementation Method 1
a cyclodextrin inclusion complex comprising a β-cyclodextrin host molecule substituted by hydroxypropyl groups (hydroxypropyl-β-cyclodextrin, or HPβCD) or by sulfopropylether groups (sulfobutylether-β-cyclodextrin or SBEβCD) and comprising a cavity containing tirapazamine as a guest
Data Source
AI summary
The present disclosure provides cyclodextrin inclusion complexes of a β-cyclodextrin substituted host molecule wherein the guest is tirapazamine. The molar ratio of the tirapazamine guest to the cyclodextrin host ranges from about 14:1 to about 2:1, inclusive. The complexed tirapazamine has advantageous properties when compared to non-complexed tirapazamine in that the tirapazamine complex is water soluble and, at a molar ratio of the β-cyclodextrin substituted host molecule to the tirapazamine guest of 2:1, the pH of a 0.7-1 mg/mL solution of the inclusion complexes containing tirapazamine ranges from about pH 5.3 to about pH 6.4. The present disclosure also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and cyclodextrin inclusion complexes of β-cyclodextrin substituted host molecules wherein the guest is tirapazamine. The pharmaceutical composition comprising the β-cyclodextrin-complexed tirapazamine demonstrates improved stability, improved solubility and reduced toxicity of the tirapazamine compared to non-complexed tirapazamine alone.